CRDFCardiff Oncology, Inc.

$139M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$141,000+51.6% YoY

Gross Profit

$34,00024.1% margin

Operating Income

-$11M-7673.8% margin

Net Income

-$10M-6901.4% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+30.6%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$955,000

Balance Sheet

Total Assets

$88M

Total Liabilities

$11M

Stockholders' Equity

$78M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$141,000	$93,000	+51.6%
Gross Profit	$34,000	$93,000	-63.4%
Operating Income	-$11M	-$9M	-20.3%
Net Income	-$10M	-$9M	-13.5%

CRDF Q3 2023 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena